Research Article

Safety of Technique and Procedure of Stromal Vascular Fraction Therapy: From Liposuction to Cell Administration

Karina Karina, Iis Rosliana, Imam Rosadi, Rachel Schwartz, Siti Sobariah, Irsyah Afini, Tias Widyastuti, Melinda Remelia, Komang Ardi Wahyuningsih, and Jeanne A. Pawitan

1Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, Indonesia
2HayandraLab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta Pusat, Indonesia
3Boston Children’s Hospital, 300 Longwood Ave, Boston, MA, USA
4Department of Basic Biomedicine, Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia
5Department of Histology, Universitas Katolik Indonesia Atma Jaya, Jakarta, Indonesia
6Department of Histology, Faculty of Medicine, Universitas Indonesia, Jl. Salemba 6, Jakarta Pusat, Indonesia
7Stem Cell Medical Technology Integrated Service Unit, Dr. Cipto Mangunkusumo General Hospital/Faculty of Medicine, Universitas Indonesia, Jl. Diponegoro 71, Jakarta 10430, Indonesia
8Stem Cell and Tissue Engineering Research Center, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jl. Salemba 6, Jakarta 10430, Indonesia

Correspondence should be addressed to Karina Karina; karina@hayandra.com

Received 7 January 2020; Revised 24 April 2020; Accepted 12 June 2020; Published 6 July 2020

Academic Editor: Umit Tursen

Copyright © 2020 Karina Karina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Stromal vascular fraction (SVF) therapy has been performed over the past six years to treat 421 patients by our group in five clinical centers. Autologous SVF, which is a substance containing stem cells, was isolated from lipoaspirate, mixed with platelet-rich plasma (PRP), and administered to patients with degenerative diseases, autoimmune diseases, trauma, aging, and other diseases with unknown etiology. This study aimed to determine the safety of SVF and PRP that were given through infusion, spinal, and intra-articular injection. Methods. The lipoaspirate was treated with a tissue-dissociating enzyme, and then, through centrifugation, SVF was isolated. In addition, blood was drawn from each patient, and PRP was isolated. Autologous PRP and SVF were administered to all subjects by intravenous (IV) injection. A minority group within the population received an additional spinal or intra-articular injection. The type of intervention was determined by each disease evaluation. The cell doses and adverse events for each patient were documented and analyzed. Results. Cell dose that was considered to be safe was less than 10 billion SVF cells in 250 cc of normal saline, for IV injection, and less than 1 billion SVF, for intra-articular and spinal injection. Adverse events were not severe and were treated successfully. Any observed adverse events were identified as a result of spinal or intra-articular injections and were not related to SVF or PRP. Conclusions. Our results showed that administration of high dose of SVF until 10 billion cells in a majority of 421 patients through infusion, spinal, and intra-articular injection was feasible without causing major adverse events and should be further investigated in well-designed phase I-II clinical trial to address the safety and efficacy of therapy.

1. Introduction

Mesenchymal stem cells (MSCs) can be isolated from adipose tissue from patients through a simple liposuction technique [1, 2]. MSCs are particularly useful for regenerative healing because they are multipotent cells, which can differentiate into a variety of cell types [3]. After lipoaspirate processing, MSCs are obtained along with endothelial cells, macrophages, pericytes, and T cells, which together comprise a substance referred to as stromal vascular fraction (SVF), in a relative short time, usually in 2-3 hours [4, 5]. Culturing SVF leads to MSC isolation, and 1-2 week-culture
period is needed to produce millions of these fibroblast-like plastic adherent cells known as MSCs [6]. Autologous SVF extraction procedure replaces any need for allogeneic cell culturing [7], and therefore risks of contamination, aging of stem cells, or rejection can be avoided [8–10]. Moreover, the procedure is less expensive. Therefore, many therapies were performed using autologous SVF rather than autologous or allogeneic MSCs [7].

Recently, researchers reported immunomodulation effect of MSCs in experimental autoimmune disease. MSCs can inhibit proliferation of T cell from lymph nodes of encephalomyelitis, reduce IFN-γ production by T cell, and significantly inhibit total antigen specific IgG production, as well as that of each IgG subclass [11]. MSCs also secrete various factors to reduce proinflammatory cytokine such IL-6 and TNFα that may be useful for treating inflammatory diseases such as cystic fibrosis lung disease [12]. It is well known that MSCs secrete proangiogenic cytokines, such as vascular endothelial growth factor (VEGF), angiopoietin-1 (Angpt-1), hepatocyte growth factor (HGF), and insulin-like growth factor-binding proteins (IGFBPs) to promote cells regeneration [13]. To date, stromal or mesenchymal stem cell application has been used to treat many diseases and conditions, including osteoarthritis [14], rheumatoid arthritis [15], chronic obstructive pulmonary disease (COPD) [16], heart disease, Lyme disease, Crohn’s disease/coliitis, autoimmune diseases, diabetes, lower limb vascular disease, kidney failure, neurological symptoms, degenerative disc disease, vaginal dryness, urinary incontinence, hair loss and alopecia [17], fat grafting [18], multiple sclerosis [19], and retinitis pigmentosa [20] and for aesthetic purposes [21].

Platelet-rich plasma (PRP) has high growth factors content [6, 7]. In in vitro studies, PRP was used as the source of growth factors to support MSC proliferation and differentiation [6, 22–25], replacing the use of animal-derived serum. In animal and human studies, PRP was used for accelerating wound healing process [26], improving regeneration of injured articular cartilage [6, 7], reversing hypertrophic scars [21], and reducing the necrosis that frequently occurred in fat graft procedure [27].

Most researchers showed safety and potential benefits of SVF therapy, and all collected data indicated evidence of a safe procedure. In fact, SVF and PRP therapy have been performed in Indonesia since 2011. However, Indonesian recent regulation in 2018 required any cell therapy, including SVF therapy, to be conducted on the basis of clinical trial in order to prove safety and efficacy. In this article, we report our experience in combining SVF and PRP therapy since 2011 to treat degenerative diseases, autoimmune diseases, trauma, and other diseases, in addition to using them as antiaging therapy. Those SVF and PRP were processed using several methods that include the use of commercial kit and laboratory-based developed methods. The purpose of this article is to provide supportive knowledge regarding the process of SVF and PRP preparation for clinical application; the highest dose of SVF has been administered through infusion, spinal, and intra-articular injection without tolerable side effects. In addition, we present precautions for avoiding major unwanted side effects in future clinical trials investigating the safety and efficacy of this therapy in certain diseases.

2. Methods

This was a retrospective study involving patients that were treated with autologous SVF and PRP for a variety of conditions. The fat aspiration procedures were mostly performed by a single operator in five clinical sites in Jakarta, Indonesia. Most of the administration procedures were done in Hayandra Clinic by the physician with specific competencies (internist, neurologist, plastic surgeon, and antiaging doctors). Ethical clearance was obtained from Health Research Ethics Committee, University of Indonesia, and Cipto Mangunkusumo Hospital (HREC-FMUI/CMH) with letter of approval No. 0249/UN2.F1/ETIK/2018. Previously recorded medical data was collected from the medical records documented by the clinics or hospitals.

2.1. Group of Pathology. Patients were divided into 5 groups, namely, involving antiaging, degenerative diseases, autoimmune diseases, trauma, and unknown etiology such as hearing loss. Degenerative diseases involved diabetes melitus, degenerative musculoskeletal disease, cardiovascular and metabolic disease, stroke, brain disorder, respiratory disease, renal failure, degenerative brain disease, eye disease, neurological disorder, and reproductive system, while autoimmune diseases involved autism and autoimmune disease.

2.2. SVF Processing Method. SVF is a heterogeneous mixture of cells that includes endothelial cells, erythrocytes, fibroblasts, macrophages or other immune cells, progenitor, pericytes, and also MSCs [5]. In this study, SVF refers to all cell types in the fraction. SVF was processed using three different methods, referred to as Methods 1, 2, and 3. Adipose tissue was collected from abdominal fat tissue for adults and thigh paediatric for children (aged below 15 years). Liposuction technique was aspirated manually using 2.4 mm cannula with tunesmetic technique for anesthesia.

In Method 1, SVF was isolated from liposapirate by commercial kit as described by the manufacturer. Briefly, about 15–600 mL of fat was collected by syringe and stored in 50 mL tube. SVF cells were extracted from fat using the extraction kits according to the manufacturer’s guideline. Fats were washed 3 times with saline solution and then incubated with commercial enzyme for 30 minutes. The sample was centrifuged for 10 min, 3000 rpm, to collect SVF as pellet at the bottom of the tube. The cells were filtered using 100 µm pore size cell strainer (Gibco, USA). To collect the SVF, cells were then centrifuged for 10 min, 3000 rpm, at room temperature.

Method 2 is available method provided by a stem cell laboratory in Jakarta. About 15–600 mL of fat was stored in 50 mL tube and then washed with saline solution. The fat tissues were then digested by in house enzyme for 1 hour at 37°C. The fats were washed with saline solution, followed by
centrifugation for 5 min at 600 × g. The supernatant was discarded to get SVF.

Method 3 was invented by HayandraLab, as an improvement to the previous method, and was referred to as the H-Remedy method (patent application no. P00201603083) [28]. Lipoaspirates (about 15–600 mL) were digested by H-Remedy enzyme and incubated for 1 hour at 37°C, 300 rpm. After incubation, the digested lipoaspirates were added to low-glucose (1 g/L) Dulbecco’s modified Eagle’s medium (DMEM) containing 4 mM glutamine (Gibco, USA) to inactivate the enzyme, followed by centrifugation for 5 min at 600 × g. Then, the supernatant was discarded. The cell number and viability were counted by trypan blue staining. Calculation of live cells used the following formula:

\[
\text{Number of cells} = \frac{\text{average live or dead cells}}{4 (\text{chambers})} \times Df \times 10^4 \times \text{cell suspension volume},
\]

where Df is the dilution factor.

The following formula was used to calculate cell viability:

\[
\text{Cell viability} = \frac{\text{average live cells}}{\text{average live + dead cells}} \times 100\%.
\]

In our previous publications, SVF isolated using each method has been characterized. Cultured SVF is reported to express CD73, CD90, and CD105 without or with less expression of CD34/CD45/CD11b/CD19/HLA-DR, which are able to differentiate into chondrocyte, osteocyte, and adipocyte that meet criteria of MSCs as defined by the International Society of Cellular Therapy [24, 25].

2.3. Platelet-Rich Plasma Processing Method. Platelet-rich plasma (PRP) was prepared using two different methods: the commercial kit (Platelet-Rich Plasma Kit, AdiStem Ltd., Hong Kong) and the conventional method, which was invented and developed by HayandraLab. In brief, 24 cc samples of whole blood were collected from each respective patient, in a sodium citrate tube, and centrifuged at low speed for 5 minutes until the plasma layer separated from the red blood cell (RBC) layer. Plasma was aspirated, collected, and subjected to second centrifugation step, requiring high speed for another 5 minutes until platelets were concentrated at the bottom of the tube. Plasma was removed until the final volume of plasma remaining in the tube was 3 cc. The pellet of platelets was resuspended in the remaining plasma in the tube (3 cc), which was regarded as inactivated PRP. This 3 cc of PRP was then activated using calcium chloride solution until a clot was formed. Clots were removed to isolate the PRP, and the PRP was subjected to light activation (AdiLight-1, AdiStem Ltd., Hong Kong). The laser-activated PRP was used in combination with SVF. The light activation was conducted to increase anti-inflammatory cytokine, such as interleukin-1 receptor antagonist (IL1-RA) levels in PRP [29]. This protocol was applied in Methods 1, 2, and 3.

It was noted, during the use of commercial kit, that the protocol of PRP preparation was changed based on the instruction from the kit manufacturer. The newest protocol of Method 1 demonstrated that there was no need for PRP activation using calcium chloride. However, our group found that clot formation and removal from PRP were important in the case of intravenous injection, which demanded a different protocol to generate the most safe and effective therapy.

2.4. SVF Administration. The SVF pellet was resuspended in 0.9% normal saline, resulting in a total of 22 mL SVF suspension. We used 7 mL of cell suspension for quality control (contamination, endotoxin, and MSCs culture). A total of 15 mL SVF suspension was mixed with 3 mL autologous PRP that had been activated previously using calcium chloride solution, and light therapy by AdiStem Ltd. Photobiostimulation. A total of 20 mL SVF and PRP suspension was injected into an infusion bag, which contained 250 mL of 0.9% normal saline, if the total cell number was more than 1 billion. If the cell number was less than 1 billion, the normal saline volume was 100 mL. The mixture of SVF and PRP together was then infused intravenously to each patient over duration of 30 minutes. Patients were treated with a range between 1 and 3 separate SVF-PRP infusions. Time at which patients received SVF-PRP procedures also determines numbers of infusions since sufficient number of SVFs for repeated infusions was only received after SVF process was performed using H-Remedy method. In addition, three repeated infusions were only done after we validated a method to store SVF in nitrogen liquid tank and to thaw the cells while still resulting in sufficient number of cells that is more than 100 million cells for the third infusion. Number of repeated injections also depends on the case and needs of each patient, as determined by patient medical conditions, such as severity of illness and disease duration. For example, patients with disease duration more than a year or with moderate to severe diseases were given at least two infusions. However, if cell number is sufficient for three infusions, patients not meeting those criteria also received three infusions. The first infusion was done on the day of their liposuction procedure, followed by another infusion in two weeks apart.

Patients with osteoarthritis received additional intra-articular injections, with a total of 3 mL in each affected knee, which made the treatment more closely focused on a specific area. Patients who had presented with cerebral palsy, autism, stroke, Parkinson’s disease, and dementia also received one spinal injection of SVF on the day of their liposuction procedure, at the same time of receiving their first infusion of SVF intravenously, in order to augment the strength and force of the treatment. In the cases which received an additional injection, 3 mL of the SVF and PRP mixture collected was used for spinal injection for autism and brain-related disorder or intra-articular injection for osteoarthritis patients. The remaining cell suspension was injected into the infusion bag containing 250 mL of 0.9% normal saline, or 100 mL depending on the SVF number.
3. Results

3.1. Patient Demographics and SVF Procedure. Among 421 patients, 194 patients (46%) were male and 227 (54%) patients were female. The median age was 55 years old. The youngest patient studied was 1 year old, and the oldest patient was 86 years old.

Patients were divided into sixteen groups based on their pathological conditions (Figure 1). The full distribution of categories, including the number of patients, age, gender, volume of fat cells processed, SVF processing method used, number of repetitions of treatment, cell dose given, and route of administration per disease group, is presented in Table 1.

Disease groups were sorted from the most to the least common cases, as per percentage values. The top 5 common diseases during the study were diabetes mellitus, antiaging, degenerative musculoskeletal disease, cardiovascular and metabolic disease, and autism. Other treated diseases can be seen in Table 1.

SVF was mostly isolated using H-Remedy method (330 patients, 78%), followed by commercial kit (82 patients, 19%) and then available method (9 patients, 3%) being the least used method. All patients received SVF through IV administration, while some received additional intra-articular and spinal injection, depending on the disease and condition, which has been taken into consideration during the overall evaluation. All patients who were treated during the period when Method 1 and Method 2 were being used received only one treatment. Method 3 implemented additional series of infusions, which was important in ultimate healing and treatment progress, which was observed in the success of the treatments, as documented. From a group of 330 patients, 193 patients received three series of infusion, 123 patients received one infusion only, and 105 patients received two infusions. Each infusion was received in 2 weeks apart. After cell counting, the viability of isolated SVF from all patients was more than 90%, regardless of SVF isolation method used, which was important for the efficacy and safety of the treatment. The distribution of cell doses administered via IV, intra-articular, and spinal injection is presented in Table 2.

3.2. Intravenous Injection. The concentrations of SVFs within the first infusion received by 421 patients varied between 1 million to 26.12 billion cells. A large portion of patients received between 1 and 5 billion SVFs (221 patients, 52%), followed by the next majority group who received 100 million to 1 billion SVFs (73 patients, 17%) and the last majority group having received 5–10 billion SVFs (53 patients, 13%). Only 23 patients (5%) received less than 100 million SVFs. Seven patients (2%) received more than 10 billion SVFs in first infusion. SVF records were not available for 44 patients (11%) in Method 1 group, which was one of the limitations for this study. The number of cells infused was dependent on the isolation process and the unique composition of SVFs within adipose tissue of each individual. Overall, the median dose of cell population within the first SVF infusion was calculated as 1.93 billion.

For the second SVF infusion, which was received by 298 patients, the number of injected SVFs varied between 0.03 billion and 9.64 billion cells. Half of the patients received 1–5 billion SVFs (147 patients, 50%), followed by 100 million to 1 billion SVFs (138 patients, 46%). Nine patients (3%) received SVFs ranging from 5 to 10 billion cells, and 4 patients (1%) received fewer than 100 million SVFs. The median number of SVFs injected was 1.02 billion cells.

In the cases of patients who received three SVF infusions (193 patients), the number of SVFs injected during the third and final treatment ranged between 0.10 billion and 3.04 billion cells. Seventy-four percent of patients (143 patients) received between 100 million and 1 billion SVFs, and the remaining patients (50 patients) received between 1 and 5 billion SVFs. No patients received an SVF infusion containing less than 100 million cells or more than 5 billion cells. Overall, the median number of cells within the SVF at the 3rd infusion was 0.64 billion cells. The number of cells infused has been compared to the efficacy and overall outcome of each patient’s treatment progression.

3.3. Intra-Articular Injection. A total of 47 patients who had presented with osteoarthritis and other musculoskeletal diseases, specifically concerning the knees, received intra-articular injections of SVF in the affected areas. The number of SVFs injected into the affected knees varied from 1 million to 1.60 billion cells. Patients commonly received less than 1 billion cells (27 patients, 57%). The median dose of SVFs for intra-articular injections was 0.17 billion SVFs per each affected knee. Thirteen patients (28%) received less than 100 million cells, and only 3 patients (6%) received 1 to 5 billion cells. Data was lost for 4 osteoarthritis patients (9%).

3.4. Spinal Injection. In total, seventy-six patients received SVF through spinal injections. The median number of cells administered was 0.28 billion, ranging from 0.001 billion cells to 4.12 billion cells. More than half of the patients (47 patients, 62%) received less than 1 billion SVFs, followed by patients who received less than 100 million SVFs (13 patients, 17%). Only three patients (4%) received between 1
and 5 billion SVFs, which was the smallest amount administered. Data was lost for 13 patients (17%) during the use of Method 1.

3.5. Safety Analysis and Management. All of evaluated patients experienced immediate hematoma growth surrounding the entry site for liposuction procedure and general inflammation. Mild analgesics, taken three times daily for a three-day duration, were used to provide relief of symptoms reported, including hematoma growth, inflammation, and mild to moderate pain and discomfort. Out of all patients recorded, two patients reported uniquely extreme discomfort at the liposuction site, which was not relieved within the initial 3 days. These patients in particular were advised to continue the analgesic regimen for an additional two weeks. For the two patients who required additional pain management, all symptoms were relieved within the following two weeks of treatment, using mild painkillers.

11 patients (3%) reported that they experienced shivering, which lasted for several minutes after procedure and diminished after 1 ampoule of corticosteroid was administered through IV infusion. This side effect was only reported during the period when SVF was isolated using Method 1 techniques, which contributed towards the termination of this method being used. Patients were prescribed a 3-day oral medication regimen, immediately following surgery, including either paracetamol or ketorolac and cefixime or ciprofloxacin, as was decided for each individual patient. The SVF from those 11 patients was processed using the same batch of kits provided by Method 1 processing manufacturers. Microbial tests were performed, to check for sterility of the kits, by an authorized laboratory. These tests confirmed that the reagent (used to dissociate the fat tissue and free the stem cells) from the suspected batch, which produced adverse results, was contaminated by *Enterobacter cloacae* and *Klebsiella oxytoca* bacterium. The manufacturer had released nonsterile processing kits due to mal-production, and therefore our group switched from using Method 1 to using a new method, referred to as Method 2.

During the time when Method 1 was used, one patient experienced thrombus formation in left anterior inferior cerebellar artery. This patient received nonactivated PRP administered by IV injection, due to the change of the protocol of the manufacturer of the commercial PRP kit. This patient recovered ultimately after successful thrombus removal treatment, which was performed in the hospital. After this incident, all of the patients received PRP that has been activated by calcium chloride solution, which gave successful outcomes with all of them. Among the patient population (76 patients) who have been treated with a spinal injection, five patients (7%) reported to have experienced headaches and discomfort, which lasted within the first week following the injection. All of the patients found relief of symptoms within one week of beginning analgesic treatment.
Table 1: Distribution of patients’ conditions (age, gender), median of fat tissue processed, SVF processing method, repetition of treatment, and cell dose for IV injection based on pathological condition.

| Group of disease | Pathological condition | Number of patients | Median of age, min and max (year) | Median of fat tissue volume, min and max (cc) | Number of patients | Median of total cell dose, min and max (billion) for IV | Repetition of treatment |
|------------------|------------------------|--------------------|-----------------------------------|-----------------------------------------------|-------------------|-------------------------------------------------------|------------------------|
|                  |                        | N % M F            | 1 2 3 4 5                         | 1 2 3 4 5                                      | 1 2 3 4 5         | 1 2 3 4 5                                              | 1 2 3 4 5              |
| Diabetes mellitus| DM type 1 and 2         | 140 33.25 93 47    | 56 (13–85)                        | 145 (20–393)                                   | 20 4 116 33 38 69 | 2.42 (0.003–19.24)                                    | 1.00 (0.03–8.48)       |
|                  |                        |                    |                                  |                                               |                   | 0.72 (0.13–2.92)                                      |                        |
| Antiaging        | Systemic rejuvenation  | 72 17.10 19 53     | 51 (34–84)                        | 130 (15–613)                                   | 9 1 62 22 18 32  | 2.08 (0.20–11.80)                                     | 1.02 (0.10–8.12)       |
|                  |                        |                    |                                  |                                               |                   | 0.62 (0.18–2.08)                                      |                        |
| Degenerative musculoskeletal disease | Osteoarthritis, osteoporosis, and herniated nucleus pulposus | 47 11.16 14 33 | 64 (10–86)                        | 183 (50–445)                                   | 11 1 35 13 11 23 | 1.11 (0.001–10.12)                                    | 0.92 (0.15–9.64)       |
|                  |                        |                    |                                  |                                               |                   | 0.44 (0.10–2.40)                                      |                        |
| Cardiovascular and metabolic disease | Cardiomyopathy, hypertension, postcardiac stenting | 26 6.18 19 7 | 57 (4–71)                        | 181 (45–445)                                   | 7 0 19 8 10 8    | 2.00 (0.04–8.18)                                     | 0.97 (0.11–5.07)       |
|                  |                        |                    |                                  |                                               |                   | 0.88 (0.21–2.10)                                      |                        |
| Autism           | Autism                 | 25 5.94 18 7       | 10 (5–34)                         | 108 (30–326)                                   | 11 0 14 12 5 8   | 2.04 (0.001–4.24)                                     | 1.57 (0.13–9.64)       |
|                  |                        |                    |                                  |                                               |                   | 0.95 (0.13–1.64)                                      |                        |
| Autoimmune disease | Multiple sclerosis, myasthenia gravis, psoriasis, and vasculitis | 24 5.70 6 18 | 41 (16–69)                        | 101 (30–323)                                   | 6 0 18 6 5 13    | 2.30 (0.02–7.25)                                     | 1.12 (0.08–2.96)       |
|                  |                        |                    |                                  |                                               |                   | 0.69 (0.32–3.04)                                      |                        |
| Stroke           | Chronic ischemic stroke| 22 5.23 14 8       | 57 (32–75)                        | 120 (40–399)                                   | 2 0 20 4 5 13    | 1.47 (0.40–19.60)                                    | 0.82 (0.08–2.64)       |
|                  |                        |                    |                                  |                                               |                   | 0.63 (0.10–2.65)                                      |                        |
| Brain disorder/brain damage | Epilepsy, cerebral palsy, postmeningitis related brain injury, postraumatic brain damage, post-cholecirconioma | 21 4.99 16 5 | 12 (1–44)                        | 65 (15–375)                                   | 4 0 17 7 7 7    | 1.52 (0.04–26.12)                                    | 1.20 (0.20–3.82)       |
|                  |                        |                    |                                  |                                               |                   | 0.59 (0.14–1.08)                                      |                        |
| Respiratory disease | COPD                   | 13 3.09 10 3       | 68 (48–78)                        | 230 (58–349)                                   | 7 0 6 7 2 4      | 1.39 (0.002–8.82)                                     | 1.77 (0.60–5.84)       |
|                  |                        |                    |                                  |                                               |                   | 0.61 (0.40–1.28)                                      |                        |
| Renal failure    | Chronic renal failure  | 8 1.90 5 3         | 67 (45–76)                        | 209 (93–305)                                   | 3 0 5 3 1 4      | 1.74 (1.16–4.17)                                     | 1.73 (1.20–3.94)       |
|                  |                        |                    |                                  |                                               |                   | 0.76 (0.51–1.39)                                      |                        |
| Degenerative brain disease | Parkinson’s, dementia, Alzheimer | 8 1.90 6 2 | 61 (55–77)                        | 98 (60–200)                                   | 0 3 5 3 0 5      | 1.22 (0.24–2.68)                                     | 0.28 (0.22–0.83)       |
|                  |                        |                    |                                  |                                               |                   | 0.49 (0.13–1.03)                                      |                        |
| Eye disease      | Macular degeneration, retinitis pigmentosa | 5 1.19 3 2 | 71 (49–77)                        | 120 (80–200)                                   | 2 0 3 2 1 2      | 1.04 (0.14–3.05)                                     | 0.44 (0.33–0.82)       |
|                  |                        |                    |                                  |                                               |                   | 0.66 (0.31–1.01)                                      |                        |
| Neurological disorder | Mental retardation, hypoconcentration | 3 0.71 1 2 | 27 (21–55)                        | 60 (37–120)                                   | 0 0 3 2 0 1      | 1.96 (0.31–2.24)                                     | 0.16 (0.14–3.05)       |
|                  |                        |                    |                                  |                                               |                   | 0.10 (0.31–1.01)                                      |                        |
| Reproductive system target | Improving quality of sperm, dimectar | 3 0.71 1 2 | 62 (35–62)                        | 120 (100–285)                                  | 0 0 3 0 1 2      | 1.64 (1.43–2.13)                                     | 1.32 (0.45–2.76)       |
|                  |                        |                    |                                  |                                               |                   | 0.63 (0.55–0.71)                                      |                        |
| Posttrauma injury | Multiple fracture, urethrae rupture, and skin loss after trauma | 2 0.48 1 1 | 43 (17–69)                        | 121 (120–121)                                  | 0 0 2 1 0 1      | 4.81 (1.44–8.18)                                     | 0.44 (0.28–0.63)       |
|                  |                        |                    |                                  |                                               |                   | 0.48 (0.28–0.63)                                      |                        |
| Hearing problem  | Deafness and hearing loss | 2 0.48 1 1 | 36 (22–50)                        | 179 (130–228)                                  | 0 0 2 0 1 1      | 3.80 (2.31–5.29)                                     | 1.90 (1.16–2.64)       |
|                  |                        |                    |                                  |                                               |                   | 0.77 (0.16–1.08)                                      |                        |

Total 421 100 194 227 82 9 330 123 105 193

Method 1: SVF was isolated from lipoaspirate by commercial kit. Method 2: available method provided by stem cell laboratory in Jakarta. Method 3: H-Remedy established by HayandraLab.
4. Discussion

Considering available publications that were reviewed, it is believed that our group is the first to treat patients with the largest dose of SVF concentrations recorded, administered through more than one route, including intravenous (IV), intra-articular (IA), and spinal injection. In practice, we used calcium chloride–light irradiation–activated PRP that is safe for IV administration, which augmented the therapy and produced better results for the patients. Previous studies had proved that light activation reduces production of proinflammatory interleukin-1α, IL-2, IL-5, and IL-6 and increases anti-inflammatory factor, IL-10, secretion in T cell culture [30]. The benefit of using light irradiation to activate PRP was reported in osteoarthritis patients [31]. Rodriguez reported the treatment of 12 rheumatoid arthritis patients using SVF containing 16–45 million cells per IV injection, and each patient received a maximum of four injections. However, there was no clear explanation for the volume of saline solution or the time of infusion in this study [15]. In another phase I clinical trial, conducted by Comella et al., twelve patients with end-stage COPD were treated with one single SVF infusion [32]. The range of SVF dosing given to each patient varied from 150 to 300 million cells, in combination with 1000 mL saline solution. Infusion was administered over the course of 2 hours, via the antecubital vein. Another multicenter study was published by the same author group, Comella et al., in which 246 patients were treated with autologous SVF and PRP [18]. The systemic symptoms and diseases that were treated included COPD, heart disease, Lyme disease, Crohn’s disease/collitis, various autoimmune diseases, diabetes, and kidney failure [18]. SVF was administered by IV injection throughout a duration of 30–60 minutes via bolus push, and the cell dose was between 30 and 60 million cells in 3–5 mL of 0.9% normal saline. Another 3–5 mL of normal saline was infused to clear the line. In the same study, 93 patients who had presented with neurological symptoms were treated with SVF intrathecally via lumbar puncture, 33 patients with degenerative disc disease were treated with 1 mL of SVF and PRP mixture by an intradiscal injection, 264 patients with orthopedic symptoms received intra-articular SVF and PRP injection (3–5 mL), 7 patients received SVF and PRP injection into the scalp for hair loss, and 1 patient received intramuscular SVF and PRP injection of 5–10 mL mixture of SVF and PRP into their legs to target vascular disease. Several other patients received SVF infusion, along with a fat transfer procedure, and a total of five patients received injections of 5 mL SVF and PRP in their sex organs for degenerative conditions [18]. Riordan et al. published three case reports of SVF therapy for multiple sclerosis patients [33]. Three patients received two IV injections of 25, 28, and 75 million SVFs every 10 days, followed by multiple intrathecal and IV infusions of allogeneic CD34+ and MSCs [33].

We observed that a majority of these published studies used not more than 100 million SVFs, except one study which was done by Comella et al. [32]. It is hypothesized that the fundamental reason for the use of this smaller amount of injected SVFs in clinical application is likely the inability of investigators to isolate large number of cells from adipose tissue collected from their patients. Most of the stem cell studies also used this general number range of stem cells, likely due to high costs and cumbersome technique necessary to provide large number of stem cells [34]. One exception was particular autologous human adipose-derived MSCs (ADMSCs) study by Ra et al. in spinal cord injury (SCI) patients [35]. In this ADMSCs study, eight SCI patients were treated with one IV infusion of 400 million autologous ADMSCs. The cells were divided into four doses, resulting in one infusion bag which consisted of 100 million cells per 100 mL normal saline (1 million cells/mL). The cells were then injected into the cephalic vein over the course of 3 to 4 h [35].

We considered that determining the optimal dose is a crucial step for establishing an effective cell therapy. It is generally expected that number of cells administered will be proportionate to the efficacy. Koga et al. reported that higher number of implanted rabbit synovium-derived MSCs improved cartilage regeneration in animal model [36]. Another previous study reported that the amounts of cartilage matrix and proteoglycan were higher in composites consisting of $10^7$ cells than those consisting of lower cell densities ($10^6$ and $10^7$ MSCs) [37]. However, these findings were not consistent with other studies. In a dose escalation study reported by Park et al., efficacy of human umbilical cord blood-derived MSCs for cartilage repair was higher in lower MSC doses (0.1, 0.5, and $10^7$ cells) than those in higher dose ($10^7$ cells) [38]. It might be proper to consider several factors such as the source of the cells, their characteristic, and route and delivery vehicle for cell

| Table 2: Cell doses for IV, intra-articular, and spinal injection. |
|---------------------------------------------------------------|
| **Median (min–max) cells dosage (billion)** | <100 million cells | <1 billion cells | 1 to 5 billion cells | 5 to 10 billion cells | >10 billion cells | No data | Total |
|-----------------|------------------|----------------|------------------|-------------------|-----------------|---------|-------|
| 1st infusion    | 1.93 (0.001–26.12) | 23            | 73              | 221              | 53              | 7       | 44    | 421   |
| 2nd infusion    | 1.02 (0.03–9.64)  | 4             | 138             | 147              | 9               | 0       | 0     | 298   |
| 3rd infusion    | 0.64 (0.10–3.04)  | 0             | 143             | 50               | 0               | 0       | 0     | 193   |
| Intra-articular injection | 0.17 (0.001–1.60) | 13           | 27              | 3                | 0               | 0       | 0     | 47    |
| Spinal injection | 0.28 (0.001–4.12) | 13           | 47              | 3                | 0               | 0       | 0     | 76    |

Patients with osteoarthritis and other degenerative musculoskeletal diseases in knees got additional intra-articular injection, and those who had presented with cerebral palsy, autism, stroke, Parkinson’s disease, and dementia also got additional spinal injection of SVF on the day of first infusion.
administration, as well as patient condition, in determining the optimal dose in stem cell therapy. Based on our clinical experience, greater improvements for patient symptomatology were achieved when patients received higher number of SVFs. It is plausible that when intravenously administered, the stem cells traveling through the bloodstream are distributed to a less concentrated area of tissues, resulting in only low detectable level of injected cells in target tissue, compared with that of intra-articular injected cells, in one specific region of the body [39]. Moreover, we have confirmed in our previous in vitro research that culture SVF isolated from diabetic patients formed less colonies than those isolated from nondiabetic patients [40]. Similar results were obtained from MSCs from aged donors that also show reduced viability, cell growth, increase of cell senescence, and superoxide dismutase (SOD) activity [41]. Therefore, it is important that the number of viable SVFs is as high as possible, so that the injected cells can reach target tissue in an optimum number to compensate for the reduced biological function of cells from aging or degenerative diseases, thus being most effective for regeneration.

The next thing to consider in determining the dose in cell therapy is the safety of the cell dose for the patient. In this study, in all cases, the majority of patients received less than 10 billion SVFs. We noted that 6 out of 7 patients who received more than 10 billion SVFs did not report any incidence of discomfort or any side effects. However, we consider that the highest number of SVFs which can be infused to the patient is 20 billion cells, to avoid the cytokine storm-like side effect.

In the case of spinal injection, 8% of the patients experienced discomfort and incidence of experiencing headaches following spinal injection. Headaches may have been experienced following spinal injections due to repetitive insertion and removal of the spinal needle. Upon repetitive puncturing of the spinal cord, a leak in the dura becomes more likely. In the case of a leak in the dura, if any small amount of cerebrospinal fluid escapes, cushioning around the brain is reduced, and therefore a lower pressure system surrounding the brain causes moderate headaches. This symptom would continue while the dura heals. Patients who reported discomfort and headaches were prescribed mild analgesic medication and found relief of symptoms within one week of beginning mild treatment. Given uncomplicated symptom resolution, the evaluated symptoms can be associated with incidence of imprecise needle insertion instead of the cell doses, since the majority of cell doses for spinal injection are less than 1 billion. Imprecise needle insertion can be considered a human error, which would not concern the treatment itself.

Based on our previous study, we also notice that protocol for isolating the cells should be feasible, optimum for cells isolation (number and viability) [42], and also free of contamination. The reported median viability of SVF was higher than the minimum acceptable viability specification for somatic cell therapy, generally set at 70% [43]. Viability of cell product more than 70% has not demonstrated any adverse effects on the safety and efficacy of product administration for therapy. In this study, all SVFs processed have viability more than 90%, so there are no negative side effects reported as outcome for low viability cells in this study.

The most prevalent incidence of reported side effects is experiencing shivering, which was determined as being due to contamination from the kit of Method 1. It became important to test the sterility of the kit or reagent used for cell isolation, as it became clear that the manufacturer could not guarantee kit sterility. It was determined that one advantage of using Method 3 isolation protocol, developed at HayandraLab, is that we ensure that each material and treatment method is at minimum risk of contamination, and it is manageable to ensure sterility and safety.

We are aware that one source of contamination throughout the procedure could be the lipoaspirate collection itself, due to the presence of skin bacteria. In taking steps for reducing and preventing any serious side effects, related to bacteria contamination, we injected each patient with preoperative antibiotics (third-generation cephalosporins) and prescribed each patient a 3-day oral medication regimen immediately following the procedure, consisting of NSAID and antibiotic medications. Another opportunity for contamination to be aware of is tumor contamination. Garcia et al. found minimal tumor contamination present in their human MSC culture [44]. In our practice, SVF was combined with PRP, which is rich with various growth factors. Tumor cells can utilize these growth factors to support their proliferation and migration. Considering that there is no conclusive result present today about bi-modal effect of stem cells on cancer patient, we considered that noncancer patient selection is important in the case of autologous SVF and PRP therapy, in order to find the most appropriate candidates for this treatment, to ensure safety, and identify patients who will benefit the most.

Our study showed that SVF therapy is a feasible, effective, and safe treatment method. As an autologous SVF therapy, SVF therapy proposes no specific threats, as demonstrated from 421 accounts of patient records. The cell dose that is considered to be tolerable with no patient’s complaint or discomfort was a concentration of less than 10 billion SVFs in 250 cc of normal saline, for IV injection, and less than 1 billion SVFs, for intra-articular and spinal injection. We recommend that volume of saline solution used for IV injection and rate of infusion should be proportionate to the SVF number. A higher number of SVFs, over 20 billion cells, was considered to be potentially overwhelming and harmful to the patient and has not been tested. The majority of reported adverse events in this study were low risk, manageable, temporary, and expected outcomes of the SVF procedure. SVF can be combined with PRP in clinical practice and is beneficial to the outcome of the patients’ recovery, as found through clinical implementation.

PRP contains highly concentrated platelets. Marx reported that double centrifugation of autologous blood can produce PRP with concentration of platelets of at least $1 \times 10^9$ cell/µL that is almost 5 times higher than the platelet concentration in the whole blood [45]. Platelets from majority of our patients, especially those who have diabetes, were easier to aggregate after second centrifugation as we
observed in laboratory, which may reflect their behavior in blood circulation [46]. Aggregated platelet releases various cytokines and growth factors that in turn activate endothelium [47]. Activated endothelium recruits more platelets and circulating immune cells to adhere to and form plaque. Plaques that are ruptured can damage endothelium causing thrombus formation and vascular occlusion that might happen in one of our patients who received PRP without prior ex vivo platelet activation. Thus, for IV injection, PRP should be activated prior to infusion in order to avoid thrombus formation. This order of injection has demonstrated evidence of success and has not caused thrombus formation. In SVF-PRP therapy, noncancer patient screening is needed to avoid tumor contamination within SVF and has been effective in the present clinical treatment.

Our results showed that administration of high dose of SVF until 10 billion cells in a majority of 421 patients through infusion, spinal, and intra-articular injection was feasible without causing major adverse events. However, our study was done in retrospective manner, was not designed as a dose escalating study, and lacks some clinical data to draw reliable conclusion for determining the highest dose of SVF that is safe for clinical application. While phase I-II clinical study is sorely needed to address the highest tolerable dose of SVF, repetition, and safety, as well as potential benefit of this therapy in certain diseases, our study still offers some knowledge for researchers and clinicians working in the same area to improve their procedures, such as SVF-PRP processing and therapy.

5. Conclusions

Our results showed that administration of high dose of SVF until 10 billion cells in a majority of 421 patients through infusion, spinal, and intra-articular injection was feasible without causing major adverse events and should be further investigated in well-designed phase I-II clinical trial to address the safety and efficacy of the therapy.

Abbreviations

ADMScs: Adipose-derived MSCs
COPD: Chronic obstructive pulmonary disease
IA: Intra-articular
IV: Intravenous
MSCs: Mesenchymal stem cells
PRP: Platelet-rich plasma
SCI: Spinal cord injury
SVF: Stromal vascular fraction.

Data Availability

The data used to support the findings of this study are included within the article.

Ethical Approval

This study was approved by the Health Research Committee, Faculty of Medicine, Universitas Indonesia (No. 0249/UN2.F1/ETIK/2018).

Consent

Informed consent was provided before samples were collected from patients.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

KRN designed and improved the concept of the protocol of stromal vascular fraction therapy; informed the patients about diagnosis, procedure, indication of the procedure, risk and complication, prognosis, other alternative treatment or medication, prior to obtaining the informed consent, and patient medication and management plan; performed liposarpirate isolation from majority of the patients (more than 95%); and evaluated patients’ health conditions before and after procedure. MRA invented the protocol of stromal vascular fraction isolation. MRA, SSH, and IRI validated the protocol. IRI, SSH, IAI, and TWI performed stromal vascular fraction isolation and collected data records. IRA and IRI contributed to data acquisition, management, and statistical analysis. KRN, KAW, IRA, and JAP interpreted the results and contributed to the discussion. IRA and RSZ wrote the article. KRN, KAW, JAP, and MRA reviewed the article. JAP came up with ideas for improving the quality of the article.

Acknowledgments

The authors acknowledge H-Clinic, Dharma Nugraha Hospital, CBC Beauty Care, YPK Mandiri Hospital, Melinda II Hospital, and Hamrin Hospital Salemba for the permission to access their patients’ medical records, limited to those treated with stromal vascular fraction processed by H-Remedy method in HayandraLab, for the purpose of the scientific study.

References

[1] P. A. Zuk, M. Zhu, P. Ashjian et al., “Human adipose tissue is a source of multipotent stem cells,” Molecular Biology of the Cell, vol. 13, no. 12, pp. 4279–4295, 2002.
[2] J. A. Pawitan, “Prospect of adipose tissue derived mesenchymal stem cells in regenerative medicine,” Cell & Tissue Transplantation & Therapy, vol. 2, pp. 7–9, 2009.
[3] N. Kim and S.-G. Cho, “Clinical applications of mesenchymal stem cells,” The Korean Journal of Internal Medicine, vol. 28, no. 4, pp. 387–402, 2013.
[4] K. Yoshimura, T. Shigeura, D. Matsumoto et al., “Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates,” Journal of Cellular Physiology, vol. 208, no. 1, pp. 64–76, 2006.
[5] Karina, J. A. Pawitan, and I. Rosadi, “Adipose-derived stem cells and their microenvironment (Niche) in type 2 diabetes mellitus,” Stem Cell Investigation, vol. 7, no. 2, 2020.
[6] P. Van Pham, K. H. T. Bui, D. Q. Ngo, T. T. P. Doan et al., “Expanded adipose tissue-derived stem cells for articular cartilage injury treatment: a safety and efficacy evaluation,” in
Regenerative Medicine, N. Bhattacharya and P. Stubblefield, Eds., pp. 113–123, Springer, London, UK, 2015.

[7] P. Van Pham, K. Hong-thienn Bui, D. Quoc Ngo, L. Tan Khuat, and N. Kim Phan, “Transplantation of nonexpanded adipose stromal vascular fraction and platelet-rich plasma for articular cartilage injury treatment in mice model,” Journal of Medical Engineering, vol. 2013, Article ID 832396, 7 pages, 2013.

[8] K. Kornicka, K. Marycz, K. A. Tomaszewski, M. Marędziak, and A. Śmieszek, “The effect of age on osteogenic and adipogenic differentiation potential of human adipose derived stromal stem cells (hASCs) and the impact of stress factors in the course of the differentiation process,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 309169, 20 pages, 2015.

[9] M. Marędziak, K. Marycz, K. A. Tomaszewski et al., “The influence of aging on the regenerative potential of human adipose derived mesenchymal stem cells,” Stem Cells International, vol. 2016, Article ID 2152435, 15 pages, 2016.

[10] K. Kornicka, J. Szlapka-Koszarewska, A. Śmieszek, and K. Marycz, “5’-Azacytidine and resveratrol reverse senescence and ageing of adipose stem cells via modulation of mitochondrial dynamics and autophagy,” Journal of Cellular and Molecular Medicine, vol. 23, no. 1, pp. 237–259, 2019.

[11] E. Gerdoni, B. Gallo, S. Casazza et al., “Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis,” Annals of Neurology, vol. 61, no. 3, pp. 219–227, 2007.

[12] T. L. Bonfield, D. Lennon, S. K. Ghosh, A. M. DiMarino, A. Weinberg, and A. I. Caplan, “Cell based therapy aides in infection and inflammation resolution in the murine model of cystic fibrosis lung disease,” Stem Cell Discovery, vol. 3, no. 2, pp. 139–153, 2013.

[13] G. DiMarino, B. Hosseinikhani, S. Kuypers et al., “Angiogenic effects of human dental pulp and bone marrow-derived mesenchymal stromal cells and their extracellular vesicles,” Cells, vol. 9, no. 2, p. 312, 2020.

[14] N. Yokota, M. Yamakawa, T. Shirata, T. Kimura, and H. Kaneshima, “Clinical results following intra-articular injection of adipose-derived stromal vascular fraction cells in patients with osteoarthritis of the knee,” Regenerative Therapy, vol. 6, pp. 108–112, 2017.

[15] J. P. Rodriguez, M. P. Murphy, S. Hong et al., “Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety,” International Archives of Medicine, vol. 5, pp. 1–9, 2012.

[16] W. Broekman, P. P. S. J. Khedoe, K. Schepers, H. Roelofs, J. Stolk, and P. S. Hiemstra, “Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease?” Thorax, vol. 73, no. 6, pp. 565–574, 2018.

[17] H. Fukuoka and H. Suga, “Hair regeneration treatment using adipose-derived stem cell conditioned medium: follow-up with trigonometers,” Eplasty, vol. 26, no. 15, pp. 65–72, 2015.

[18] K. Comella, M. Parlo, R. Daly et al., “Safety analysis of autologous stem cell therapy in a variety of degenerative diseases and injuries using the stromal vascular fraction,” Journal of Clinical Medicine Research, vol. 9, no. 11, pp. 935–942, 2017.

[19] O. Fernández, G. Izquierdo, V. Fernández et al., “Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase II/II safety and feasibility study,” PLoS One, vol. 13, no. 5, Article ID e0195891, pp. 1–14, 2018.

[20] R. C. Siqueira, A. Messias, J. C. Voltarelli, I. U. Scott, and R. Jorge, “Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy,” Retina, vol. 31, no. 6, pp. 1207–1214, 2011.

[21] S. Domergue, C. Bony, M. Maumus et al., “Comparison between stromal vascular fraction and adipose mesenchymal stem cells in remodeling hypertrophic scars,” PLoS One, vol. 11, no. 5, Article ID e0156164, 2016.

[22] D. Suryani, J. A. Pawitan, J. Lilianty, R. Y. Purwoko, J. K. Liem, and L. Damayanti, “Comparison of fetal bovine serum and platelet-rich plasma on human liposarprate-derived mesenchymal stem cell proliferation,” Medical Journal of Indonesia, vol. 22, pp. 146–151, 2013.

[23] P. Sari, E. Luviah, R. Y. Purwoko, and J. A. Pawitan, “A Proliferation and surface marker characterization of adipose stem cells after culture in various processed outdated platelet lysate containing media,” International Journal of PharmTech Research, vol. 10, no. 2, pp. 120–130, 2017.

[24] I. Rosadi, K. Karina, I. Rosliana et al., “The effect of human platelet-rich plasma and l-ascorbic acid on morphology, proliferation, and chondrogenesis ability towards human adipose-derived stem cells,” Molecular and Cellular BioMedical Sciences, vol. 3, no. 1, pp. 26–33, 2019.

[25] I. Rosadi, Karina, I. Rosliana et al., “In vitro study of cartilage tissue engineering using human adipose-derived stem cells produced by platelet-rich plasma and cultured on silk fibroin scaffold,” Stem Cell Research and Therapy, vol. 10, p. 369, 2019.

[26] M. R. Mahmoudian-Sani, F. Rafaei, and M. Saidijam, “The effect of mesenchymal stem cells combined with platelet-rich plasma on skin wound healing,” Journal of Cosmetic Dermatology, vol. 17, no. 5, pp. 650–659, 2018.

[27] J. Lack, O. J. Smith, and A. Mosahbeh, “A systematic review of autologous platelet-rich plasma and fat graft preparation methods,” Plastic and Reconstructive Surgery Global Open, vol. 5, no. 12, p. e1586, 2017.

[28] K. F. Moegni, I. Rosliana, M. Remelia et al., “Stromal vascular fraction (SVF) therapy for treatment of various diseases: delivering safety of the first patented SVF technique in Indonesia,” Cytotherapy, vol. 21, no. 5, p. S86, 2019.

[29] J. Freitag, “The effect of photoactivated platelet-rich plasma injections in the novel treatment of shoulder osteoarthritis,” International Journal of Case Reports and Images, vol. 5, no. 8, p. 546, 2014.

[30] H. Sigmundsdottir, A. Johnston, J. E. Gudjonsson, and H. Valdimarsson, “Narrowband-UVB irradiation decreases the production of pro-inflammatory cytokines by stimulated T cells,” Archives of Dermatological Research, vol. 297, no. 1, pp. 39–42, 2005.

[31] K. A. Peterson, M. Nicholls, K. L. Bennell, and D. Bates, “Intra-articular injection of photo-activated platelet-rich plasma in patients with knee osteoarthritis: a double-blind, randomized controlled pilot study,” BMC Musculoskeletal Disorders, vol. 17, p. 67, 2016.

[32] K. Comella, J. A. P. Blas, T. Ichim, J. Lopez, J. Limon, and R. C. Moreno, “Autologous stromal vascular fraction in the intravenous treatment of end-stage chronic obstructive pulmonary disease: a phase I trial of safety and tolerability,” Journal of Clinical Medicine Research, vol. 9, no. 8, pp. 701–708, 2017.

[33] N. H. Riordan, T. E. Ichim, W. P. Min et al., “Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis,” Journal of Translational Medicine, vol. 13, no. 5, Article ID e0195891, pp. 1–14, 2018.

[34] A. Goldberg, K. Mitchell, J. Soans et al., “The use of mesenchymal stem cells for cartilage repair and regeneration: a
systematic review,” *Journal of Orthopaedic Surgery and Research*, vol. 12, no. 1, pp. 1–30, 2017.

[35] J. C. Ra, I. S. Shin, S. H. Kim et al., “Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans,” *Stem Cells and Development*, vol. 20, no. 8, pp. 1297–1308, 2011.

[36] H. Koga, T. Muneta, T. Nagase et al., “Comparison of mesenchymal tissues-derived stem cells for in vivo chondrogenesis: suitable conditions for cell therapy of cartilage defects in rabbit,” *Cell and Tissue Research*, vol. 333, no. 2, pp. 207–215, 2008.

[37] A. Yokoyama, I. Sekiya, K. Miyazaki, S. Ichinose, Y. Hata, and T. Muneta, “*In vitro* cartilage formation of composites of synovium-derived mesenchymal stem cells with collagen gel,” *Cell and Tissue Research*, vol. 322, no. 2, pp. 289–298, 2005.

[38] Y. B. Park, C. W. Ha, J. A. Kim et al., “Effect of transplanting various concentrations of a composite of human umbilical cord blood-derived mesenchymal stem cells and hyaluronic acid hydrogel on articular cartilage repair in a rabbit model,” *PLoS One*, vol. 11, no. 11, pp. 1–14, 2016.

[39] B. Wagner and R. Henschler, “Fate of Intravenously injected mesenchymal stem cells and significance for clinical application,” in *Mesenchymal Stem Cells-Basics and Clinical Application II*, pp. 19–37, Springer, Berlin, Germany, 2012.

[40] K. Karina, I. Rosliana, S. Sobariah et al., “Diabetes mellitus type 2 reduces the viability, proliferation, and angiogenic marker of adipose-derived stem cells cultured in low-glucose anti-oxidant-serum supplemented medium,” *Biomedical Research and Therapy*, vol. 6, no. 3, pp. 3073–3082, 2019.

[41] M. S. Choudhery, M. Badowski, A. Muise, J. Pierce, and D. T. Harris, “Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation,” *Journal of Translational Medicine*, vol. 12, no. 1, p. 8, 2014.

[42] M. Remelia, I. Rosadi, I. Rosliana et al., “Optimized method for isolation of regenerative stromal cells from human liposaspirates,” *Biomedical Research and Therapy*, vol. 4, p. S47, 2017.

[43] S. R. Bauer, “Stem cell-based product in medicine: FDA regulatory consideration,” in *Handbook of Stem Cells*, pp. 805–814, Elsevier Academic Press, Cambridge, MA, USA, 2004.

[44] S. Garcia, M. C. Martín, R. de la Fuente, J. C. Cigudosa, J. Garcia-Castro, and A. Bernad, “Pitfalls in spontaneous in *vitro* transformation of human mesenchymal stem cells,” *Experimental Cell Research*, vol. 316, no. 9, pp. 1648–1650, 2010.

[45] R. E. Marx, “Platelet-rich plasma: evidence to support its use,” *Journal of Oral and Maxillofacial Surgery*, vol. 62, no. 4, pp. 489–496, 2004.

[46] Karina, K. A. Wahyuningsih, S. Sobariah et al., “Evaluation of platelet-rich plasma from diabetic donors shows increased platelet vascular endothelial growth factor release,” *Stem Cell Investigation*, vol. 6, p. 43, 2019.

[47] D. Huang, M. Refaat, K. Mohammadi et al., “Macrovacular complications in patients with diabetes and prediabetes,” *Biomedical Research International*, vol. 2017, Article ID 7839101, 9 pages, 2017.